PhRMA, Sen. Grassley Dispute Over “Whistleblower” Law Wanes
This article was originally published in The Pink Sheet Daily
Executive Summary
Finance Chairman says the latest letter from the trade group regarding efforts to prevent fraudulent drug pricing and billing practices is more encouraging than their initial exchange. PhRMA says it will be in touch with committee staff to further discuss False Claims Act issues.